NCT04554095

Brief Summary

Weaning from mechanical ventilation (MV) is a complex process in which patients are liberated from the ventilator. Prolongued weaning and weaning failure, defined as the need for reintubation, have different adverse effects, including prolongation of MV, intensive care unit (ICU) and hospital stay, and are also associated with increased incidence of ventilator-associated pneumonia and high mortality. The rate of weaning failure is high, even when the classic extubation criteria are met, so it is necessary to improve scores that allow predicting and determining the ideal time for MV withdrawal. The aim of this study is to design a new multimodal index to predict and optimize weaning results in a personalized way, based on the use and interpretation of data derived from continuous monitoring of critically ill patients. The new multimodal index, in addition to classical respiratory parameters, will include parameters related to patient-ventilator interaction (asynchronies), diaphragmatic function, cardiovascular status and autonomic nervous system function (ANS). The investigators have designed a prospective observational study that will include 126 critical patients from a medical-surgical ICU that meet the classical criteria for weaning. The management of the patients, as well as the weaning process, will be carried out following the usual protocol. In addition to the classical weaning predictor data, data on the patient-ventilator interaction and the function of the autonomic nervous system will be collected by means of specific software (BetterCare). Cardiovascular and diaphragmatic function will be evaluated using ultrasound. Based on the advanced analysis of data from different devices collected throughout the mechanical ventilation period, it will be designed a "personalized" weaning score that should improve the accuracy of the decision-making process and therefore reduce morbidity and mortality. Additional benefits would include lowering health care costs without increasing adverse events.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
126

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2020

Completed
18 days until next milestone

First Posted

Study publicly available on registry

September 18, 2020

Completed
1.5 years until next milestone

Study Start

First participant enrolled

April 4, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

February 7, 2024

Status Verified

February 1, 2024

Enrollment Period

2 years

First QC Date

August 31, 2020

Last Update Submit

February 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Multimodal index for weaning prediction evaluation

    Number of successful weanings evaluated through the new multi-modal index compared to the classic indexes

    48 hours after mechanical ventilation withdrawal

Secondary Outcomes (1)

  • Predictive value of patient-ventilator interaction

    From day 1 of mechanical ventilation until 48 hours after mechanical ventilation withdrawal

Interventions

Respiratory parameters, analytic values, lung ultrasound and echocardiography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients admitted to the ICU of the Parc Taulí Universitary Hospital undergoing MV and starting the weaning process according to the protocol established for usual clinical care practice.

You may qualify if:

  • Patients with MV\> 24 hours.
  • Patients with orotracheal tube.
  • Patients who meet the classic criteria of weaning from the MV defined as:
  • Improvement or resolution of the cause required for MV. PaO2\> 60mmHg with FiO2≤0.4 and PEEP ≤8cm H2O. Glasgow Coma Score\> 10 Temperature \<38 ° C. Hemoglobin\> 8g / dL No need for vasoactive drugs or at doses \<5μg / kg / min Obtaining informed consent.

You may not qualify if:

  • Tracheostomy patients.
  • Patients with neurological pathology with involvement of the brainstem.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Candelaria De Haro

Sabadell, Barcelona, 08208, Spain

RECRUITING

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor and Doctor of Philosophy

Study Record Dates

First Submitted

August 31, 2020

First Posted

September 18, 2020

Study Start

April 4, 2022

Primary Completion

April 1, 2024

Study Completion

December 1, 2024

Last Updated

February 7, 2024

Record last verified: 2024-02

Locations